

Variant: *NM\_000546.6(TP53):c.1146del (p.Lys382fs)*

Version: 1.0

CA497711354 [↗](#)

1408583 (ClinVar) [↗](#)

**Gene:** TP53 ([HGNC:7157](#))

**Condition:** Li-Fraumeni syndrome ([MONDO:0018875](#))

**Inheritance Mode:** Autosomal dominant inheritance

**UUID:** cbf33d9d-4af0-4b9d-bc0d-163d4df14e20

**Approved on:** 2025-05-07

**Published on:** 2025-07-18

## HGVS expressions

### NM\_000546.6:c.1146del

NM\_000546.6(TP53):c.1146del (p.Lys382fs)

NC\_000017.11:g.7669650del

CM000679.2:g.7669650del

NC\_000017.10:g.7572968del

CM000679.1:g.7572968del

NC\_000017.9:g.7513693del

NG\_017013.2:g.22906del

ENST00000503591.2:c.1146del

ENST00000508793.6:c.1146del

ENST00000509690.6:c.750del

ENST00000514944.6:c.867del

ENST00000604348.6:c.1125del

ENST00000269305.9:c.1146del

ENST00000269305.8:c.1146del

ENST00000359597.8:c.994-3401del

ENST00000413465.6:c.782+4536del

ENST00000420246.6:c.\*253del

ENST00000445888.6:c.1146del

ENST00000455263.6:c.\*165del

ENST00000504290.5:c.\*165del

ENST00000504937.5:c.750del

ENST00000510385.5:c.\*253del

ENST00000576024.1:c.99del

ENST00000610292.4:c.1029del

ENST00000610538.4:c.\*165del

ENST00000610623.4:c.\*165del

ENST00000615910.4:c.1113del

ENST00000617185.4:c.\*253del

ENST00000618944.4:c.\*253del

ENST00000619186.4:c.669del

ENST00000619485.4:c.1029del

ENST00000620739.4:c.1029del

ENST00000622645.4:c.\*253del

ENST00000635293.1:c.983+964del

NM\_000546.5:c.1146del

NM\_001126112.2:c.1146del

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | NM_001126113.2:c.*165del<br>NM_001126114.2:c.*253del<br>NM_001126115.1:c.750del<br>NM_001126116.1:c.*253del<br>NM_001126117.1:c.*165del<br>NM_001126118.1:c.1029del<br>NM_001276695.1:c.*165del<br>NM_001276696.1:c.*253del<br>NM_001276697.1:c.669del<br>NM_001276698.1:c.*253del<br>NM_001276699.1:c.*165del<br>NM_001276760.1:c.1029del<br>NM_001276761.1:c.1029del<br>NM_001276695.2:c.*165del<br>NM_001276696.2:c.*253del<br>NM_001276697.2:c.669del<br>NM_001276698.2:c.*253del<br>NM_001276699.2:c.*165del<br>NM_001276760.2:c.1029del<br>NM_001276761.2:c.1029del<br>NM_001126112.3:c.1146del<br>NM_001126113.3:c.*165del<br>NM_001126114.3:c.*253del<br>NM_001126115.2:c.750del<br>NM_001126116.2:c.*253del<br>NM_001126117.2:c.*165del<br>NM_001126118.2:c.1029del<br>NM_001276695.3:c.*165del<br>NM_001276696.3:c.*253del<br>NM_001276697.3:c.669del<br>NM_001276698.3:c.*253del<br>NM_001276699.3:c.*165del<br>NM_001276760.3:c.1029del<br>NM_001276761.3:c.1029del |
|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Likely Pathogenic

Met criteria codes 4

PM2\_SupportingPP1PVS1\_ModeratePS4\_Moderate

Not Met criteria codes 6

BS1BS3PM1PS3BA1PP4

Evidence Links 0

Expert Panel

TP53 VCEP

Criteria Specification Information

Criteria Specification: ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.3.0

Criteria Specification Approval History

Criteria Specifications for this VCEP

Evidence submitted by expert panel

TP53 VCEP

The NM\_000546.6 c.1146del (p.Lys382AsnfsTer?) is a TP53 frameshift variant inducing a stop codon read-through. The variant is predicted to escape nonsense mediated decay, targeting a region of unknown function representing <10% of the protein and introducing a C-terminal extension of 28 residues in the protein (PVS1\_Moderate). This variant has been reported in 3 unrelated families meeting Revised Chompret criteria and reported in 1 individual under the age of 40 diagnosed with a HER2+ breast cancer. Based on this evidence, this variant scores 2 total points meeting the TP53 VCEP phenotype scoring criteria of 2-3.5 points. (PS4\_Moderate; Internal lab contributors). The variant has been reported to segregate with LFS-associated cancers in 3-4 meioses in 1 family (PP1; Internal lab contributors). This variant has an allele frequency of 6.196e-7 (1/1614052 alleles) across gnomAD v4.1.0 which is lower than the Clingen TP53 VCEP threshold (<0.00003) for PM2\_Supporting and has no more than one allele per non-bottleneck subpopulation (PM2\_Supporting). In summary, this variant meets the criteria to be classified as Likely Pathogenic for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: PVS1\_Moderate, PS4\_Moderate, PP1, PM2\_Supporting. (Bayesian Points: 6; VCEP specifications version 2.3)

Met criteria codes

|                |                                                                                     |                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|----------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PM2_Supporting |    |    | This variant has an allele frequency of 6.196e-7 (1/1614052 alleles) across gnomAD v4.1.0 which is lower than the Clingen TP53 VCEP threshold (<0.00003) for PM2_Supporting and has no more than one allele per non-bottleneck subpopulation (PM2_Supporting).                                                                                                                                                                                                                                                                                                                                                                                               |
| PP1            |    |    | The variant has been reported to segregate with LFS-associated cancers in 3-4 meioses in 1 family (PP1; Internal lab contributors).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| PVS1_Moderate  |    |    | The NM_000546.6 c.1146del (p.Lys382AsnfsTer?) is a TP53 frameshift variant inducing a stop codon read-through. The variant is predicted to escape nonsense mediated decay, targeting a region of unknown function representing <10% of the protein and introducing a C-terminal extension of 28 residues in the protein (PVS1_Moderate). It’s right at the end of the gene and predicted to cause a fs then a protein extension of 28 aa’s. Not predicted to be subject to NMD or NSD. Affects <10% of protein and not a functional domain although 3 of the aa’s affected are highly conserved but no pathogenic missense variants reported in this region. |
| PS4_Moderate   |  |  | This variant has been reported in 3 unrelated families meeting Revised Chompret criteria and reported in 1 individual under the age of 40 diagnosed with a HER2+ breast cancer. Based on this evidence, this variant scores 2 total points meeting the TP53 VCEP phenotype scoring criteria of 2-3.5 points. (PS4_Moderate; Internal lab contributors).                                                                                                                                                                                                                                                                                                      |

Not Met criteria codes

|     |                                                                                     |                                                                                     |                                                                                                                                      |
|-----|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| BS1 |  |  | No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline           |
| BS3 |  |  | Additional functional studies are needed for code application (PS3/BS3 not met).                                                     |
| PM1 |  |  | This variant does not reside within a region of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PM1 not met). |
| PS3 |  |  | Additional functional studies are needed for code application (PS3/BS3 not met).                                                     |
| BA1 |  |  |                                                                                                                                      |

No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

PP4



No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

Curation History [↗](#)

▾

▾

Showing 1 to 1 of 1 rows

|  |
|--|
|  |
|--|

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.